+49.4%
SRE vs GSK
+44.4%
+4.9%
-31.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | +0.5% | +0.2% | +0.6% |
| 7D | +1.8% | +1.1% | +0.6% | +1.5% |
| 30D | -3.0% | +6.3% | -9.3% | -4.1% |
| 3M | -7.3% | +1.8% | -9.1% | -7.7% |
| 6M | -11.9% | +1.7% | -13.5% | -12.4% |
| YTD | -7.9% | +6.5% | -14.4% | -9.6% |
| 1Y | -11.1% | +9.5% | -20.6% | -13.3% |
| 3Y | +24.8% | +65.3% | -40.5% | +8.6% |
| All | +49.4% | +44.4% | +4.9% | +29.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling